GF Fund Management CO. LTD. Boosts Position in Amgen Inc. $AMGN

GF Fund Management CO. LTD. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 134,415 shares of the medical research company’s stock after acquiring an additional 6,216 shares during the quarter. Amgen comprises 0.8% of GF Fund Management CO. LTD.’s portfolio, making the stock its 27th largest holding. GF Fund Management CO. LTD.’s holdings in Amgen were worth $43,995,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. West Family Investments Inc. lifted its holdings in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC lifted its holdings in shares of Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its holdings in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. Sittner & Nelson LLC lifted its holdings in shares of Amgen by 0.4% during the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares in the last quarter. Finally, ORG Partners LLC lifted its holdings in shares of Amgen by 0.6% during the fourth quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock valued at $1,767,000 after purchasing an additional 31 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 1.7%

Amgen stock opened at $355.30 on Friday. The stock has a market cap of $191.75 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 3.65 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The stock has a fifty day moving average of $362.91 and a 200 day moving average of $337.31.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. Amgen’s dividend payout ratio is presently 70.84%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMGN. Piper Sandler upped their price target on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Truist Financial upped their price target on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Citigroup upped their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $356.24.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.